ストックスクリーナーアプリを入手
2.86
2.05%
-0.06
アフターアワーズ：
2.86
Pyxis Oncology Inc (PYXS) 最新ニュース
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Pyxis Oncology stock falls 3.73 percent after trial update - AD HOC NEWS
Pyxis Oncology Inc (PYXS) Key Financial Ratios – Valuation, Profitability & More - Value Research
Pyxis Oncology, Inc.(NasdaqGS: PYXS) added to S&P Global BMI Index - marketscreener.com
Pyxis Oncology Inc (NASDAQ: PYXS) Share Price, PYXS Stock News, PYXS Share Price & Updates - kalkine.com.au
Pyxis Oncology: Setbacks Costing Nearly 2 Years Of Recovery (NASDAQ:PYXS) - Seeking Alpha
PYXIS ONCOLOGY, INC. : WELLS FARGO RAISES TARGET PRICE TO $19 FROM $12 - webull.com
Wells Fargo raises Pyxis Oncology stock price target on MICVO data By Investing.com - Investing.com South Africa
Wedbush raises Pyxis Oncology stock price target on trial data By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright By Investing.com - Investing.com Australia
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know - webull.com
Pyxis Oncology (NASDAQ: PYXS) to Launch Phase 3 Trial for MICVO in Mid-2027 Following Promising Phase 1 Results - Kalkine Media
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright - Investing.com Nigeria
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $6 to $19 - Moomoo
Wells Fargo raises Pyxis Oncology stock price target on MICVO data - Investing.com Australia
Wedbush raises Pyxis Oncology stock price target on trial data - Investing.com India
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell CarcinomaSlideshow (NASDAQ:PYXS) 2026-09-10 - Seeking Alpha
Pyxis Oncology Slides 7% as Analysts Flag Toxicity Concerns for Lead Cancer Drug - finance.biggo.com
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug - Benzinga
Wedbush Lifts Price Target on Pyxis Oncology to $8 From $6, Keeps Outperform Rating - marketscreener.com
Pyxis Oncology shares fall 7% despite updated MICVO trial results - Yahoo Finance
PYXS: MICVO showed strong efficacy and manageable safety in advanced head and neck cancer patients - TradingView
Pyxis Oncology stock falls 7% despite positive trial data By Investing.com - Investing.com Canada
Pyxis slides after new early-stage trial data for lead asset in head and neck cancer - TradingView
Pyxis Oncology Reports 36% Response Rate in Phase 1 MICVO Study - marketscreener.com
Pyxis Oncology Reports Promising MICVO Phase 1 Results - TipRanks
Pyxis Oncology reports 36% cORR, 6.2‑month mPFS and 79% 12‑month OS probability for MICVO in 2L+ HNSCC - TradingView
Head and neck cancer drug from Pyxis Oncology (PYXS) shows tumor responses ahead of 500-patient trial - stocktitan.net
A cancer treatment showed disease control in 94% of trial patients. Pyxis plans a roughly 500-patient trial. - stocktitan.net
PYXS: MICVO achieved rapid, deep responses and strong disease control in advanced head and neck cancer - TradingView
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Pyxis Oncology Shares Gain 9.25% After HoursPyxis Oncology (NASDAQ:PYXS) - Benzinga
Pyxis Oncology to present clinical data on cancer therapy By Investing.com - Investing.com South Africa
Pyxis Oncology to present clinical data on cancer therapy - investing.com
Updated cancer-drug data will be presented Sept. 9. A Memorial Sloan Kettering expert will join Pyxis Oncology. - Stock Titan
Pyxis Oncology Names Thomas Civik CEO and Chairman Ahead of MICVO Milestones - citybiz
Pyxis Oncology Appoints Thomas Civik as CEO and Chairman of the Board - Oncodaily
Pyxis Oncology Names Thomas Civik CEO, Board Chairman - marketscreener.com
Pyxis Oncology names Thomas Civik as permanent CEO and chairman By Investing.com - Investing.com Nigeria
Pyxis Oncology, Inc. Announces Board Changes - marketscreener.com
Pyxis Oncology, Inc. Announces Appointment of Thomas Civik to Chief Executive Officer, Effective September 4, 2026 - marketscreener.com
Pyxis Oncology Elevates Thomas Civik to Permanent CEO - TipRanks
Pyxis Oncology names Thomas Civik as permanent CEO and chairman - Investing.com India
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board - manilatimes.net
Pyxis Oncology (PYXS) CEO receives 2.5M options at $3.89 - Stock Titan
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):